Company Analysis
Sign in

Lantern Pharma Inc. (LTRN)

Nasdaq: LTRN · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.5
◀ Past 6.0● Present 5.3▶ Future 5.4
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

2 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lantern Pharma Inc.’s names, not what it holds today.

Patents granted
2
2 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
18
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
LANTERN PHARMA INC. its own name
US, as the owner printed on each patent
2 granted
9 published
Lantern Pharma Inc. its own name
named as the applicant on its applications, in US
0 granted
9 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 29, 202311,739,043Illudin analogs, uses thereof, and methods for synthesizing the sameOrganic fine chemistryLANTERN PHARMA INC.
Oct 18, 202211,471,431Increasing cancer patient survival time by administration of dithio-containing compoundsPharmaceuticalsLANTERN PHARMA INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 22, 20252025/0161247METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERSPharmaceuticalsLANTERN PHARMA INC.
Mar 27, 20252025/0099406TREATING CANCERS WITH COMBINATIONS OF ACYLFULVENES WITH IBRUTINIB AND/OR BORTEZOMIBPharmaceuticalsLANTERN PHARMA INC.
Dec 26, 20242024/0428886COMPUTERIZED SYSTEMS AND METHODS FOR ENSEMBLE MODEL-BASED DRUG DISCOVERYComputer technologyLANTERN PHARMA INC.
Dec 5, 20242024/0398732Treating Cancers with Combinations of Spironolactone and AcylfulvenesPharmaceuticalsLANTERN PHARMA INC.
Oct 3, 20242024/0325328TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENEPharmaceuticalsLantern Pharma Inc.
Sep 12, 20242024/0299322TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENESPharmaceuticalsLANTERN PHARMA INC.
Sep 12, 20242024/0299316METHOD FOR TREATING CANCER WITH ACYLFULVENE AND RADIATIONPharmaceuticalsLANTERN PHARMA INC.
Mar 14, 20242024/0082181Method for Treating Blood CancersPharmaceuticalsLANTERN PHARMA INC.
Dec 14, 20232023/0399285ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAMEOrganic fine chemistryLANTERN PHARMA INC.
Oct 12, 20232023/0321015METHOD FOR TREATING RHABDOID TUMORSPharmaceuticalsLantern Pharma Inc. · patent 11,844,772 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Computer technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LTRN · research, not advice